No Data
No Data
Dongxing Securities: International beauty group's performance is slightly weak, high-quality domestic brands embrace development opportunities.
The consumer cosmetics market in our country is still relatively weak, but with internal cultivation and external environment optimization, it is the right time for high-quality domestic cosmetic brands to rise.
Lushang Freda Pharmaceutical's H1 Profit Falls 33%; Shares Jump 3%
Lushang Freda Pharmaceutical Co., Ltd. 2024 Interim Report
Summary of the semi-annual report of Lushang Freda Pharmaceutical Co., Ltd. in 2024
lushang freda pharmaceutical (600223.SH): The net income in the first half of the year was 0.127 billion yuan, a year-on-year decrease of 33.18%. It is planned to distribute a dividend of 0.5 yuan per 10 shares.
On August 23, Gelonhui announced its 2024 interim report, with operating income of 1.925 billion yuan, a 22.15% year-on-year decrease; net income attributable to the shareholders of the listed company of 0.127 billion yuan, a 33.18% year-on-year decrease; net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses of 0.112 billion yuan, a 77.19% year-on-year increase; basic earnings per share of 0.13 yuan. Proposed cash dividend of 0.5 yuan (tax included) per 10 shares. The operating income for this reporting period decreased by 22.15% compared to the same period last year, attributable to the shareholders of the listed company
Lushang Freda Pharmaceutical (600223.SH): No plans to produce functional drinks at the moment.
Lushang Freda pharmaceutical (600223.SH) stated on its interactive platform on August 5th that the company currently has no plans to produce functional beverage products.
No Data
No Data